Enfusion, Inc. (NYSE:ENFN - Get Free Report) General Counsel Matthew Campobasso sold 1,695 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total value of $19,289.10. Following the sale, the general counsel now directly owns 70,946 shares of the company's stock, valued at approximately $807,365.48. This trade represents a 2.33 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Matthew Campobasso also recently made the following trade(s):
- On Monday, March 3rd, Matthew Campobasso sold 1,081 shares of Enfusion stock. The shares were sold at an average price of $11.48, for a total value of $12,409.88.
- On Tuesday, January 7th, Matthew Campobasso sold 976 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total value of $9,886.88.
Enfusion Price Performance
Shares of NYSE ENFN traded up $0.04 during mid-day trading on Tuesday, reaching $11.15. The company's stock had a trading volume of 780,007 shares, compared to its average volume of 1,156,687. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80. The stock has a fifty day moving average of $10.99 and a two-hundred day moving average of $9.92. The firm has a market capitalization of $1.44 billion, a PE ratio of 278.69, a P/E/G ratio of 1.85 and a beta of 0.95.
Enfusion (NYSE:ENFN - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The company had revenue of $52.94 million during the quarter, compared to analysts' expectations of $53.98 million. Analysts anticipate that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of ENFN. Harbor Capital Advisors Inc. raised its stake in Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock valued at $113,000 after purchasing an additional 1,315 shares in the last quarter. Versor Investments LP purchased a new stake in shares of Enfusion during the 3rd quarter valued at about $501,000. Impax Asset Management Group plc raised its position in shares of Enfusion by 25.4% during the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company's stock valued at $6,424,000 after buying an additional 136,948 shares in the last quarter. Royce & Associates LP lifted its holdings in shares of Enfusion by 35.4% in the 3rd quarter. Royce & Associates LP now owns 99,715 shares of the company's stock valued at $946,000 after acquiring an additional 26,045 shares during the last quarter. Finally, Gladius Capital Management LP increased its stake in Enfusion by 160.5% during the third quarter. Gladius Capital Management LP now owns 69,694 shares of the company's stock worth $661,000 after acquiring an additional 42,939 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of research analysts have issued reports on ENFN shares. Piper Sandler boosted their price objective on shares of Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a research report on Monday, December 23rd. William Blair reaffirmed a "market perform" rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Stifel Nicolaus raised their price target on Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Enfusion presently has a consensus rating of "Hold" and a consensus target price of $11.13.
Check Out Our Latest Stock Analysis on ENFN
About Enfusion
(
Get Free Report)
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Featured Stories
Before you consider Enfusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enfusion wasn't on the list.
While Enfusion currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
